The short answer
TRIUMPH-6 (NCT06859268) is a Phase 3 trial of retatrutide in the maintenance of weight reduction, enrolling 643 participants. It began in March 2025 and has a primary completion date of April 2028. The field's most important open question therefore has no answer for several years.
Key facts
- Registration
- NCT06859268
- Acronym
- TRIUMPH-6
- Focus
- Maintenance of weight reduction
- Phase
- 3
- Enrolment
- 643 participants
- Started
- 5 March 2025
- Primary completion
- April 2028
- Status
- Active, not recruiting
The question it addresses
Every headline figure in this field describes weight while treatment continues. What happens afterwards is measured far less often, and where it has been measured the answer is uncomfortable: the STEP-1 extension found roughly two-thirds of the loss returning within a year of stopping semaglutide. Maintenance dosing asks whether a reduced dose can hold the result without the full treatment burden.
Why the completion date matters
TRIUMPH-6 has a primary completion date of April 2028. That needs saying clearly, because commentary tends to describe maintenance data as imminent, or as the thing the field is currently waiting on. It is neither. It is several years out, and until then every claim about durability rests on extrapolation from other compounds.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why maintenance trials take so long
The design requires participants to reach a reduction plateau first, then be randomised to a maintenance strategy, then be followed long enough for divergence to appear. That is three sequential phases rather than one. A 12-month endpoint measured after a 12-month run-in is a two-year trial before analysis, which is why maintenance evidence lags efficacy evidence across the whole class by years.
What this means for reading efficacy figures
A peak reduction figure describes a maintained state, not an achieved outcome. Retatrutide's 28.3% at 80 weeks is the reduction present while treatment continued at 12 mg. Whether any of it persists at a lower dose, or without treatment, is exactly what TRIUMPH-6 exists to find out and will not report until 2028. Reading peak figures as durable results is the single most common error in coverage of this field.
Scale and status
The trial enrolled 643 participants and began on 5 March 2025. It is listed as active but no longer recruiting. Retatrutide remains investigational in every jurisdiction throughout.
Frequently asked questions
When will maintenance data be available?
TRIUMPH-6 has a primary completion date of April 2028, with publication following after that.
Is maintenance data available for any incretin?
Cessation data exists (the STEP-1 extension is the best known), but purpose-built maintenance-dosing trials are still reading out across the class.
Why do maintenance trials take longer than efficacy trials?
They need a reduction phase, then randomisation to a maintenance strategy, then long follow-up. Three sequential stages instead of one.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- TrialClinicalTrials.gov: TRIUMPH-6 (NCT06859268)clinicaltrials.gov
- RefTrajectory of weight regain after cessation of GLP-1 RAs. eClinicalMedicinethelancet.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Retatrutide Expanded Access: What It Actually IsA pre-approval expanded access record for retatrutide is listed as available. What expanded access means, who it is for, and what it is emphatically not.
- The Compounded GLP-1 CrackdownThe FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List in April 2026, closing the last legal route for mass compounding.
- MHRA Drug Safety Update: Semaglutide and NAIONOn 5 February 2026 the MHRA warned of a likely association between semaglutide and NAION, a rare optic neuropathy, estimated at up to 1 in 10,000 users.
- Target Trial Emulation: Making Observational Data BehaveA method for analysing routine health records as though a trial had been designed. Why it exists, what it fixes, and what it cannot fix.
- What the Cardiovascular and Kidney Data Actually IsA 2025 target trial emulation examined GLP-1 outcomes in adults with obesity. What that design can support, and how it differs from a randomised trial.